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Abstract Aims/hypothesis: Alpha1-proteinase inhibitor
(α1-PI) has been considered a key player in inflammatory
processes. In humans, the main production site of α1-PI is
the liver, but other tissues, including pancreatic islets, also
synthesise this molecule. The aims of this study were to
assess the islet cell types that produce α1-PI, to determine
whether α1-PI is actually secreted by islet cells, and to
assess how its production and/or secretion are regulated.
Methods: Expression of α1-PI in human islet cells was
assessed by immunofluorescence, electron microscopy
and western blotting. Release of α1-PI was analysed by
reverse haemolytic plaque assay and ELISA. The effects
of cytokines on α1-PI synthesis and secretion were tested.
Results: Immunofluorescence showed that alpha and delta
cells do express α1-PI, whereas beta cells do not. By
electron microscopy, we demonstrated a colocalisation of
α1-PI with glucagon and somatostatin within secretory
granules. Immunolabelling also revealed localisation of
α1-PI within the Golgi apparatus, related vesicles and
lysosomal structures. The expression of α1-PI in islet cells
was also demonstrated by western blotting and ELISA of
protein extracts. ELISA and reverse haemolytic plaque
assay showed that α1-PI is secreted into the culture me-
dium. Treatment of islet cells with IL-1β and oncostatin M
for 4 days increased the production and release of α1-PI.
Conclusions/interpretation: Our results demonstrate that
α1-PI is expressed by the alpha and delta cells of human
islets, and that proinflammatory cytokines enhance the
production and release of this inhibitor.
Keywords Human islets . IL-1β . Oncostatin M .
α1-Proteinase inhibitor . Reverse haemolytic plaque assay
Abbreviations OSM: oncostatin M . α1-PI:
alpha1-proteinase inhibitor . RHPA: reverse haemolytic
plaque assay
Introduction
Alpha1-proteinase inhibitor (α1-PI) is a 52-kDa acute
phase protein that inhibits serine proteases, especially
elastase, which is released by human neutrophils during
inflammatory processes [1]. Deficiency of α1-PI is as-
sociated with chronic liver disease, and is often associated
with pulmonary emphysema. In humans, the liver is the
major site of expression of α1-PI. Hepatocytes synthesise
and secrete systemic α1-PI, and plasma concentrations
of α1-PI acutely increase three to four-fold in response
to ‘secondary cytokines, such as members of the IL-6
family, including IL-6 itself, leukaemia inhibitory factor
and oncostatin M (OSM) [2, 3]. It is thought that α1-PI
is involved in the tissue repair reactions that follow
inflammation.
The way secreted α1-PI acts as an anti-inflammatory
agent is not well understood. The inactivation of proteo-
lytic enzymes, such as serine proteinases of inflammatory
cells is undoubtedly of key importance, but various obser-
vations indicate that other mechanisms are also involved.
Thus, α1-PI has a neutrophil chemoattractant activity [4,
5], induces changes in neutrophil shape, and increases cell-
to-substrate adhesion [5] and spreading of smooth muscle
cells in a fibrin gel [6]. Moreover, this molecule also acts as
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a secretagogue, since it induces degranulation of neutro-
phils [5] and, if complexed with elastase, increases its own
synthesis by macrophages [7]. α1-PI may also have a
protective effect against factors inducing apoptosis by a
mechanism unidentified to date. Thus, α1-PI has been
shown to specifically inhibit the apoptosis of hepatocytes
induced by tumor necrosis factor [8], as well as that
induced by prolonged ischaemia followed by reperfusion
of organs in vivo [9]. It has been also suggested that α1-
PI may act as an antioxidant, given its high content in
methionine [10].
Although the liver is the major site of expression of α1-
PI, many studies have shown that this molecule is also
synthesised in other tissues and organs, in response to an
inflammatory insult. For instance, lung epithelial cells
respond dramatically to OSM, a cytokine of the IL-6 fam-
ily, by synthesising and secreting α1-PI [11–14]. In addi-
tion, local inflammatory conditions have been shown to
upregulate the production of α1-PI by monocytes [15],
corneal cells [16], enterocytes and Paneth cells [17], and
articular chondrocytes [18]. Taken together, these data
indicate that local production of α1-PI may contribute to
the defence of tissues against different types of injuries.
Preservation of a sufficient cell mass and function by
endogenous mechanisms capable of protecting against cell
injury is particularly important for the pancreatic islets of
Langerhans. Indeed, the integrity of these micro-organs is
altered in many pathological conditions. In type 1 diabetes,
activation of autoimmune events leads to a local peri-
insular inflammation that is particularly aggressive toward
beta cells. In type 2 diabetes, amyloid deposits alter the
function and viability of beta cells [19, 20], and it is known
that α1-PI can act in vitro as an inhibitor of amyloid fibril
formation, while promoting disaggregation of β-amyloid
fibrils [21]. In pancreatitis, endocrine cells have to defend
against the aggression of proteases released as a result of
the destruction of the exocrine tissue. Finally, in islet of
Langerhans transplantation for the treatment of type 1
diabetes, islets infused into the liver are subject to inflam-
matory insults at the site of implantation in addition to
more specific insults such as immune rejection [22]. In
these situations, α1-PI could play an important protective
role in the progression of damage to beta cells. Even
though previous reports have documented the presence of
α1-PI within pancreatic islets [23–26], the type of islet
cells producing the inhibitor is still a matter of controversy.
In addition, whether islet cells secrete α1-PI, and whether
and how this secretion is regulated has not been shown.
Materials and methods
Islet isolation
Pancreases were harvested from multiorgan cadaveric do-
nors. Islets were isolated using a previously described
modification of the automated method [27, 28]. Islets were
then rinsed with CMRL 1066 medium (Sigma, St Louis,
MO), and aliquots of 20,000 islets were incubated in 30 ml
CMRL 1066 medium containing 5.6 mmol/l glucose and
supplemented with 10% fetal calf serum, 25 mmol/l N-2-
hydroxyethylpiperazine-N′-2-ethanesulfonic acid (HEPES),
2 mmol/l glutamine, 100 U/ml penicillin and 100 μg/ml
streptomycin (hereafter, referred to as complete CMRL).
After 12 h at 37°C, culture medium was changed and islets
were further cultured at 24°C for 1 to 3 days.
Islet cell preparation
Islets were washed three times with phosphate-buffered
saline without Mg2+ and Ca2+ (PBS). Aliquots of 104 islets
were resuspended in 1 ml 0.025% trypsin solution con-
taining 1 mmol/l EDTA (Gibco, Paisley, Scotland), and
incubated at 37°C for 9–10 min, with occasional pipetting
through a 1-ml plastic tip. Trypsinisation was stopped by
addition of 10 ml cold complete CMRL, and cells were
washed twice with the same medium. Cells were then
counted and aliquots of either 3×105 or 1×106 cells were
incubated for 24 h in 10-cm-diameter, non-tissue culture-
treated petri dishes containing 10 ml complete CMRL.
Culture conditions and cytokine treatment
To study the effect of cytokines on α1-PI expression by
western blotting, aliquots of 4,500 islets were seeded in
non-tissue culture-treated petri dishes (60 mm diameter)
and incubated for 4 days in the presence of 4 ml complete
CMRL medium supplemented, or not, with 1 mmol/l
dexamethasone, 20 ng/ml IL-1β (Biosource International,
Nivelles, Belgium), 20 ng/ml OSM (Biosource Interna-
tional) and 0.5 mmol/l isobutyl–methylxanthine (IBMX;
Sigma). To study the effect of cytokines on α1-PI synthe-
sis by enzyme-linked immunosorbent assay (ELISA) and
immunofluorescence, aliquots of 15×104 islet cells were
seeded onto coverslips (15 mm diameter), and placed into
a 24-well plate. Then, cells were incubated for 4 days in
the presence of 0.5 ml complete CMRL, supplemented, or
not, with 1 mmol/l dexamethasone, 20 ng/ml IL-1β, 20 ng/
ml OSM and 0.5 mmol/l IBMX. To analyse the secretion of
α1-PI, islet cells were incubated as described above except
that a serum-free complete CMRL medium was used.
Antibodies
Goat antihuman α1-PI polyclonal antibody (A-1845) was
purchased from Sigma, and rabbit antihuman α1-PI poly-
clonal antibodies were purchased from Dako (A-0012;
Glostrup, Denmark), Sigma (A-0409) and Zymed (18-
0002; San Francisco, CA, USA). Rabbit antiglucagon
(A565), somatostatin (A0566) and pancreatic polypeptide
(A0619) polyclonal antibodies were purchased from Dako.
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A guinea-pig anti-insulin polyclonal antibody was devel-
oped in our laboratory, using porcine insulin as immuno-
gen, as previously described [29].
Immunofluorescence
To analyse the expression of α1-PI and islet hormones by
immunofluorescence, aliquots of 104 islets cells were left
to attach for 60 min at 37°C into Cunningham chambers.
These chambers were rinsed with PBS, fixed in a 4%
paraformaldehyde-PBS solution for 20 min, rinsed again
with PBS and stored at 4°C. Samples of human pan-
creases were snap frozen and embedded in optimal cutting
temperature (OCT) compound (Sakura Finetek Europe
Zoeterwoude, The Netherlands). Five-micrometre sections
were prepared and fixed in 4% paraformaldehyde-PBS
solution for 20 min. Then, sections were rinsed and used
immediately for immunofluorescence labelling.
The whole immunofluorescence procedure was carried
out at room temperature and all solutions were prepared
using PBS. After fixation, cells and sections were rinsed
three times for 5 min in PBS, treated for 15 min with 0.1%
Triton X-100 and exposed to a 0.1% bovine serum albumin
(BSA) solution for 20 min. Cells were then incubated for
2 h with one, two or three of the primary antibodies, as
indicated in the Results section. The dilutions were 1:1,200
for the anti-insulin antibody, and 1:400 for the both anti-
glucagon and the antisomatostatin antibodies. For the anti-
α1-PI, dilutions were 1:1,200, 1:400 and 1:200, for the
Sigma goat antibody, and the rabbit antibodies from Sigma
and Dako, respectively.
Immunogold electron microscopy
Pellets of isolated islets were washed twice in 0.1 mol/l
phosphate buffer, followed by 5-min fixation at room
temperature in 4% paraformaldehyde and 0.1% glutaral-
dehyde, 60-min fixation in 4% paraformaldehyde (all fixa-
tives diluted in 0.1 mol/l phosphate buffer, pH 7.4). The
islets were washed three times in 0.1 mol/l phosphate
buffer, embedded in 12% gelatin and cooled on ice. Small
blocks of gelatin-embedded islets were infused with 2.3
mol/l sucrose, snap frozen in liquid nitrogen, and sectioned
with an EMFCS cryoultramicrotome (Leica Microsystems,
Wetzlar, Germany). Ultrathin sections were mounted on
Parlodion-coated copper grids. The sections were treated as
per a modification [30] of a previously described technique
[31]. Briefly, sections were sequentially incubated as
follows: twice for 2 min in 0.1% glycine (in PBS), once
for 2 min in 1% BSA (in PBS), 1 h at room temperature in
the presence of the first primary antibody, rinsed four times
for 2 min in 0.1% BSA, and exposed 20 min at room
temperature to either protein A-coated gold particles
(15 nm diameter, for islet hormones) or to goat antimouse
or antirabbit antibodies, whichever appropriate, coupled to
15-nm and to 10-nm diameter gold particles, respectively.
After two 2-min rinses in 0.1% BSA, and two 2-min rinses
in PBS, the sections were exposed for 5 min to 1%
glutaraldehyde (in 0.1 mol/l sodium phosphate buffer, pH
7.4), rinsed twice for 5 min in PBS, exposed for 1 h at room
temperature to a second primary antibody (when required),
rinsed four times for 2 min in 0.1% BSA, exposed for
20 min at room temperature to either protein A-coated gold
particles or an appropriate gold-conjugated goat antibodies,
rinsed twice 2 min in 0.1% BSA, rinsed twice for 2 min in
PBS, exposed for 5 min to 1% glutaraldehyde (in 0.1 mol/l
sodium phosphate buffer, pH 7.4), rinsed twice for 5 min in
PBS, rinsed six times for 1 min in distilled water, and
eventually stained for 5 min in 2% uranyl acetate oxalate
(pH 7), followed by 2% methylcellulose containing 0.5%
uranyl acetate. Cryosections were screened and photo-
graphed in a CM10 electron microscope (Philips, Eindho-
ven, The Netherlands).
Single immunolabelling for α1-PI was carried using the
rabbit polyclonal serum (Dako) diluted 1:40, and revealed
with a goat anti rabbit IgG serum coupled to 10-nm gold
particles (British Biocell International, Cardiff, Wales) and
diluted 1:5. Double immunolabelling for islet hormones
and α1-PI was performed using the same anti α1-PI serum
and one of the following antibodies: a mouse monoclonal
antibody against glucagon (Sigma), diluted 1:100, and
revealed with a goat antimouse IgG serum coupled to 15-
nm gold particles (British Biocell International) diluted
1:5; a goat antisomatostatin antibody (a kind gift of M.P.
Dubois), diluted 1:40, and revealed with 15-nm protein A-
coated gold particles diluted 1:150; a mouse monoclonal
against insulin (a kind gift of M.J. Storch), diluted 1:100,
and revealed with 15-nm protein A-coated gold particles
diluted 1:150.
Controls included exposure of the sections to only the
protein A-coated gold particles or to the gold-conjugated
goat antibodies against either rabbit or mouse IgGs, what-
ever was appropriate. None of these incubations resulted in
a sizeable, specific staining of the sections.
Western blot analysis
For preparation of total protein extracts, islets were
incubated under the different conditions detailed in the re-
sults, rinsed three times in PBS and lysed by sonication in
80 mmol/l Tris–HCl buffer (pH 7.4), containing 5% SDS,
5 mmol/l EDTA and a cocktail of protease inhibitors (Com-
plete Mini Protease Inhibitor Cocktail Tablets, Roche,
Rotkreuz, Switzerland), which was used as per the manu-
facturer’s recommendations. Protein content was determined
by the Bio-Rad DC protein assay reagent kit (Bio-Rad, CA).
Ten-micrograms aliquots of total proteins were diluted in
gel loading buffer (0.025 mol/l Tris pH 6.8, 0.5% SDS,
1% 2-mercaptoethanol, 0.025% bromophenol blue, 17.5%
glycerol). Aliquots were loaded on a 7.5% polyacryla-
mide-SDS gel. After separation, proteins were transferred
to a nitrocellulose membrane (Protran; Schleicher &
Schuell, Keene, NH), which was incubated overnight in
Tris-buffered saline (TBS; Tris 0.01 M, pH 7.4, 0.15 mol/l
NaCl) containing 5% non-fat dried milk and 0.1% Tween,
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and subsequently incubated for 1 h with a polyclonal
rabbit antihuman α1-PI antibody (Dako), diluted 1:2,000
in the same buffer. After extensive washes in TBS con-
taining 0.1% Tween (TBS-Tween), the membrane was
probed for 1 h with a horseradish-peroxidase-conjugated
secondary antibody against rabbit IgG (Biorad), diluted
1:6,000 in TBS-Tween, rinsed again in TBS-Tween, re-
vealed with the SuperSignal West chemiluminescent sub-
strate kit (Amersham-Pharmacia, Buckinghamshire, UK)
according to manufacturer’s instructions, and exposed for
1 min to Hyperfilm (Amersham-Pharmacia).
Expression and release of α1-PI
The islet content in α1-PI and the amounts of inhibitor
secreted in the medium were measured by ELISA (Im-
mundiagnostik, Bensheim, Deutschland).
A reverse haemolytic plaque assay (RHPA) was used as
described [32] to attribute the secretion of α1-PI to specif-
ic islet cell types. Briefly, isolated islet cells were sus-
pended in a Krebs–Ringer-bicarbonate buffer containing
12.5 mmol/l HEPES and 0.1% BSA (control KRB) and
mixed with 5% (v/v) packed sheep red blood cells (SRBC,
Behring Institute, Marburg, Germany) that had been pre-
viously coated with protein A. Then, the cells were rinsed
and incubated for 2 h at 37°C in the presence of a goat
antihuman α1-PI polyclonal antibody (Sigma), diluted
1:30 in control KRB supplemented or not with 16.7 mmol/l
glucose, 10 μmol/l forskolin and 100 nmol/l phorbol 12-
myristate 13 acetate (PMA). The cells were rinsed with
control KRB and incubated for 1 h at 37°C in the presence
of guinea pig complement (Behring Institute), diluted 1:40
in control KRB. Chambers were filled with 0.04% (wt/vol)
solution of trypan blue in control KRB, rinsed with control
KRB, and filled with Bouin’s fixative or 4% paraformal-
dehyde. After immunofluorescence for insulin or α1-PI,
the proportion of secreting cells (as determined by the
presence of a surrounded haemolytic plaque that was iden-
tified as a circular area centered on an islet cell and
containing the dark lysed erythrocytes) was determined
under a microscope equipped with a 40× objective and a
combined phase-contrast and fluorescence illumination.
Analysis was restricted to single cells that excluded trypan
blue at the end of the plaque assay. Haemolytic plaques
were not detected when SRBC not coated with protein A
were used as controls, nor when either the anti-α1-PI
antibody or complement were omitted.
Statistical analysis
Statistical analysis was performed by analysis of variance
(ANOVA) and LSD Post Hoc tests using SPSS (Statistical
Package for Social Sciences, Chicago, IL). Student’s t-test
was performed for comparison between two groups using
the Statistica software package (StatSoft, Tulsa, OK). Val-
ues of p<0.05 were considered significant.
Results
α1-PI is selectively expressed in alpha and delta cells
Expression of α1-PI was studied by immunofluorescence
on dispersed islet cells prepared from seven human pan-
creases, and cultured under conditions favouring survival
of endocrine cells. In all preparations, 13–27% of the
cells stained positively for α1-PI (means±SEM: 22.1±
2.0%), (Fig. 1a). To identify the cell types expressing α1-
PI, double staining was performed for α1-PI and either
insulin, glucagon, somatostatin or pancreatic polypeptide
(Fig. 1b). Virtually no insulin-producing beta cell and
only few pancreatic polypeptide-producing cells (PP-cells)
expressed α1-PI. In contrast, most glucagon- (alpha cells)
and somatostatin-producing cells (delta cells) were labelled
for α1-PI. This pattern was confirmed using triple immu-
nolabelling. Thus, we found no beta cell co-expressing
α1-PI, but observed that most glucagon- and somatostatin-
immunoreactive cells also expressed α1-PI (Fig. 2).
On frozen sections of four normal pancreases, immuno-
fluorescence showed α1-PI predominantly within cells
situated at the periphery of islets, most of which stained for
either somatostatin or glucagon, but did not detect the
inhibitor in the insulin-immunoreactive cells which occupy
the core of the islets (Fig. 3).
Fig. 1 α1-PI immunoreactive cells are abundant among islet cells
and correspond to alpha and delta cells. a The percentages of cells
labelled for insulin (β), glucagon (α), somatostatin (δ), pancreatic
polypeptide (PP) and α1-PI are shown. Values are the means±SEM
of three independent experiments. A minimum of 200 cells was
scored per condition and experiment. *p<0.0001 and **p<0.001
when compared with the beta-cell group (β). b The percentage of
cells co-expressing α1-PI and either insulin (β), glucagon (α),
somatostatin (δ) or pancreatic polypeptide (PP) are shown. Values
are means±SEM of three independent experiments. A total of 305
insulin-, 231 glucagon-, 82 somatostatin- and 123 pancreatic-poly-
peptide-expressing cells was scored. *p<0.0001 when compared
with the beta-cell group (β)
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α1-PI is localised in multiple secretory compartments
of glucagon- and somatostatin-containing cells
Immunolabelling of ultrathin cryosections of human islets
resulted in a specific staining for α1-PI within glucagon-
and somatostatin-expressing cells, but not within insulin-
expressing cells (Fig. 4a). In alpha and delta cells, α1-PI
was found within multiple secretory compartments, includ-
ing the stacks and vesicles of the Golgi apparatus (Fig. 5a),
the hormone-containing secretory granules (Fig. 4a–d) and
a variety of lysosomal structures (Fig. 5a). In contrast, no
labelling was observed within nuclei, mitochondria and
cell membranes (Fig. 4a, Fig. 5a).
α1-PI synthesis by islet cells is regulated by cytokine
stimulation
Isolated islet cells were cultured for 4 days in the absence
or presence of 0.5 mmol/l IBMX, 20 ng/ml IL-1β and
20 ng/ml OSM, with, or without, 1 μmol/l dexamethasone,
before α1-PI content of islet cells was measured by ELISA
after protein extraction. In the absence of dexame thasone,
IL-1β and OSM affected α1-PI synthesis poorly (Fig. 6a).
In contrast, in the presence of dexamethasone, treatment of
islet cells by both cytokines resulted in a two- to three-fold
increase in α1-PI content (Fig. 6a). Irrespective of the
presence of dexamethasone, incubation with IBMX with
the aim to increase cAMP had no effect on α1-PI synthesis
(Fig. 6a).
The effect of cytokines on α1-PI expression was further
assessed by quantifying the immunofluorescence labelling
of α1-PI, related to that of the cell hormone content. In the
presence of dexamethasone, IL-1β and OSM, but not
IBMX, significantly increased the labelling of α1-PI com-
pared with that of glucagon (Fig. 6b). This change was
due to an actual increase in immunolabelling for α1-PI,
inasmuch as the ratio of glucagon to insulin staining re-
mained unchanged (Fig. 6b).
In further experiments, cultured intact human islets were
exposed for 4 days to cytokines, in the presence or absence
of dexamethasone, and the expression of α1-PI was ana-
lysed by western blotting. Increased levels of immunore-
active α1-PI were observed in islets treated with IL-1β and
Fig. 2 α1-PI was detected in
somatostatin- but not insulin-
containing cells after triple
immunofluorescence labelling.
Insulin-expressing cells are
stained in blue (a), α1-PI-ex-
pressing cells in green (b) and
somatostatin-expressing cells in
red (c).Merged images (d) show
that beta cells do not contain
detectable levels of α1-PI,
whereas it is abundant in one
somatostatin-expressing cell (in
yellow). A phase-contrast view
of the same cells (e). Scale bar:
20 μm
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OSM, as compared with control islets (Fig. 6c). Addition of
dexamethasone resulted in a much stronger stimulation of
α1-PI expression (Fig. 6c).
α1-PI is secreted by islet cells
To assess whether α1-PI is secreted by islet cells, we
developed a RHPA that allows for a direct visualisation of
α1-PI release by individual islet cells. After a 2 h-incu-
bation in the presence of antibodies against α1-PI, and a
1-h incubation in the presence of complement, several islet
cells were surrounded by a haemolytic plaque, as judged
by the presence of dark, non-refringent red blood cell
ghosts (Fig. 7a). Immunofluorescence for insulin showed
that only non-beta cells were surrounded by a haemolytic
plaque. Immunofluorescence for α1-PI confirmed that
cells surrounded by a haemolytic plaque contained α1-PI
(Fig. 7a). Quantitative analysis showed that 16.7±0.7%
(mean±SEM of three independent experiments) of the
cells that did not stain for insulin were surrounded by a
haemolytic plaque. This percentage did not change when
cells were stimulated with glucose (16.7±0.9, n=3) or with
0.5 mmol/l IBMX+10 μmol/l forskolin+100 nmol/l PMA
(16.0±1.0, n=3).
To assess whether the release of α1-PI was regulated by
dexamethasone and cytokines, islet cells were exposed for
4 days to these agents and both the cumulated (4 day
culture, Fig. 7b) and acute release (1 h in control medium,
Fig. 7d) of α1-PI was measured by ELISA, and compared
with the release of insulin (Fig. 7c). Results show that both
chronic and acute releases of α1-PI were significantly
increased by IL-1β and OSM, but only when dexameth-
asone was present in the medium (Fig. 7b,d). In contrast,
IL-1β and OSM did not affect insulin secretion, which was
stimulated by IBMX and decreased by dexamethasone
(Fig. 7c).
Discussion
Previous reports have documented that α1-PI was pref-
erentially expressed by peripheral islet cells, but failed to
positively identify these cells [25, 26, 33]. Using different
approaches, our study documents now that, in pancreases
from brain-dead heart-beating donors, α1-PI is expressed
in differentiated alpha, delta and PP-cells, accounting for
about 22% of the isolated islet cells.
The reason why α1-PI is located preferentially in the
alpha and delta cells of human pancreatic islets, within
only a few PP-cells and not in beta cells, remains to be
understood. One possibility is that it is related to lineage
relationships between the different islet cell types. In-
deed, it has been shown that there is a close ontogenetic
relationship between pancreatic polypeptide- and insulin-
producing cells, whereas adult glucagon- and insulin-ex-
pressing cells originate from different precursors [34, 35].
Our experiments show that α1-PI is expressed in
multiple secretory compartments, including the Golgi ap-
paratus, lysosomes and secretory granules. While the
Fig. 3 α1-PI colocalises with
glucagon, but not insulin, within
intact human pancreas. Insulin-
containing cells appear in blue
(a), α1-PI-expressing cells in
green (b) and glucagon-expres-
sing cells in red (c). Merged
images (d) demonstrate that beta
cells (blue) did not contain
detectable levels of α1-PI,
whereas the inhibitor was pres-
ent in several glucagon-contain-
ing cells (in yellow). Cells
labelled only for α1-PI (green in
d) could be either delta cells or
intra-insular endothelial cells
[24]. Scale bar: 40 μm
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presence of α1-PI in the Golgi apparatus and in lysosomes
is not surprising, the finding of this inhibitor in secretory
granules containing glucagon or somatostatin is unex-
pected, in view of previous reports considering this inhib-
itor as a constitutive secretory marker [36]. In secretory
cells, trafficking from the Golgi apparatus onwards in-
volves vesicles that are either directly conveyed to the cell
surface (constitutive secretion), targeted to the lysosomal
compartments or stored in granules belonging to the
regulated secretory pathway. A genetic variant of α1-PI
with a single Arg→Met358 substitution was shown to be
transported into granules and to inhibit conversion of hor-
mones during their transit through the regulated secretory
pathway [37–39]. Also, the native form of α1-PI cells was
found at low levels in secretory granules after transfection
of MIN6 [39], suggesting that α1-PI could be allocated to
the regulated pathway. However, this finding does not
demonstrate that the α1-PI released and detected in the
medium comes from a regulated secretory pathway. Rather,
our results showing that IBMX and PMA did not stimulate
α1-PI secretion support the hypothesis that this inhibitor is
predominantly released by a constitutive pathway. Our
finding that α1-PI is localised in hormone-containing
granules, argues also for a role of this inhibitor in the
regulation of glucagon and somatostatin conversion within
differentiated islet cells. This process starts in the Golgi
apparatus and immature granules, and involves proteolytic
cleavage by a family of proteases called convertases [40].
We further show here that α1-PI expression and release
by human islets was increased by cytokines. The plasma
levels of α1-PI increase during acute and chronic inflam-
matory processes [1–3]. Certainly, the main source of this
inhibitor in humans is the liver, and the secretion of α1-PI
by hepatocytes was shown to increase in response to
proinflammatory cytokines, such as IL-1β and IL-6 [2].
Fig. 4 α1-PI was found in glucagon- and somatostatin-containing
granules, but not in insulin-containing granules. a Low-power view
of a cryosection immunolabelled for α1-PI showing the inhibitor
within the secretory granules (arrows) of glucagon- (α) and somato-
statin-containing cells (δ), but not within the granules (arrowheads)
of insulin-containing cells (β). b–d Double immunolabelling for α1-
PI and one islet hormone demonstrated co-expression of the in-
hibitor (small gold particles) and either glucagon or somatostatin
(large gold particles) within individual secretory granules of (c)
alpha and (d) delta cells. In contrast, no α1-PI was detected within
the insulin-containing granules of beta cells (b), when an antibody
was used that resulted in intense labelling of the granules of an
adjacent alpha cell (b). Scale bar: 1 μm (a), 500 nm (b–d)
Fig. 5 α1-PI was detected in multiple secretory compartments of
glucagon-producing cells. a Immunolabelling revealed α1-PI within
the Golgi apparatus (double arrowhead), the secretory granules
(arrows) and the lysosomes (single arrowheads) of a glucagon-
producing alpha cell. Note the absence of labelling in an adjacent
beta cell (β). b Omission of the antibody against α1-PI resulted in
no gold labelling of secretory granules of an alpha cell (α). Scale
bar, 1 μm (a), 500 nm (b)
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Presumably, this increase results in the inhibition of
neutrophil elastase, which breaks down connective tissue
components causing tissue damage during inflammatory
diseases. It has been suggested that extrahepatic α1-PI may
also contribute locally, within specific organs, to the re-
sponse initiated by an inflammatory or infectious process
[14, 41]. Our study extends this possibility to human
pancreatic islets, raising the question of whether α1-PI is
implicated in the protection of peripherally located islet
cells, which are preferentially exposed to the autoimmune
attacks leading to islet destruction. As in other epithelial
cell types [12, 14], dexamethasone was shown to enhance
cytokine-induced production and release of α1-PI by islet
cells. It is widely accepted that corticosteroid hormones are
involved in the regulation of immune responses and have a
potent anti-inflammatory action, via an up- or down-
regulation of several genes. Our study shows that α1-PI is
one of such genes in the islets. The effects of glucocorti-
coids on cell death and survival depend on the cell type.
For instance, these steroids induce apoptosis of cells
involved in inflammatory reactions, such as monocytes,
macrophages and T lymphocytes, but they protect some
cells of epithelial origin against apoptotic signals [42].
Many studies have examined the effects of glucocorticoids
on the function of beta cells. Under many conditions,
glucocorticoids have been shown to have a deleterious
effect on insulin secretion [43], whereas in others they have
been shown to protect islet cells partially against IL-1β-
induced inhibition of insulin secretion [44, 45]. Another
protective effect of glucocorticoids on pancreatic islets
results from the induction in the expression of Reg gene,
which has been shown to activate regeneration of beta
cells, when dexamethasone is combined with inflammatory
mediators [46].
Therefore, it is possible that the α1-PI expressed by
alpha and delta cells has an anti-inflammatory function in
human islets. Proinflammatory cytokines are critical in the
development of type 1 diabetes. These molecules are found
within the islets at the onset of diabetes [47], and have been
shown to inhibit the function of islets, by inducing DNA
damage and beta cell death [48–50].
Fig. 6 α1-PI expression within islets and islet cells is increased by
cytokines. Islet cells were incubated for 4 days, in the absence
(−Dex) or presence (+Dex) of 1 μmol/l dexamethasone. Standard
medium (control) was supplemented with 0.5 mmol/l IBMX, 20 ng/
ml IL-1β or 20 ng/ml OSM. a Proteins were extracted and α1-PI
measured by ELISA. In the absence of dexamethasone, neither
IBMX nor cytokines caused significant changes in α1-PI expres-
sion. In contrast, in the presence of dexamethasone, IL-1β and OSM
induced a 2 to 3-fold increase in α1-PI expression. Results for
control, IL-1β and OSM conditions are expressed as means±SEM of
three experiments; only one experiment was performed with IBMX.
*p<0.02 and **p<0.05 when compared with the control in the
presence of dexamethasone. b After fixation and triple immunoflu-
orescence for α1-PI, glucagon and insulin, multiple microscopic
fields from three independent experiments were quantified. Pixel
measurements for α1-PI and insulin staining were compared with
those for glucagon, and expressed as α1-PI/glucagon (solid col-
umns) and insulin/glucagon (open columns) ratios. After exposure to
either IL-1β or OSM for 4 days in the presence of dexamethasone,
labelling of α1-PI compared with that of glucagon increased, while
labelling of insulin was unchanged. *p<0.005 when compared
with control, **p<0.05 and ***p<0.01 when compared with the
corresponding insulin/glucagon group. c Human islets were incu-
bated for 4 days in the absence (−) or presence (+) of 1 μmol/l
dexamethasone, in standard medium (−) or in this medium con-
taining (+) either 20 ng/ml IL-1β or 20 ng/ml OSM. Total proteins
were extracted from islets, separated by SDS-PAGE and reacted with
an antibody against α1-PI. Under all conditions tested, α1-PI was
detected as a single band, with an apparent molecular weight similar
to that of purified human α1-PI (control). Both IL-1β and OSM
increased the expression of α1-PI, with a synergistic effect in the
presence of dexamethasone. This panel is representative of three
different experiments
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Further in-vitro experiments are needed to verify that
α1-PI is really involved in protecting islet cells from the
injury caused by cytokines, such as IL-1β, TNF-α and
IFNγ [51]. In this regard, it is interesting to note that IL-6, a
cytokine related to OSM, was shown to confer protection to
pancreatic islet beta cells from cytokine-induced cell death
[52]. It will also be important to assess the expression of
α1-PI in islets of diabetic patients. One implication of our
study is that the expression of α1-PI should be affected in
islets showing a well-characterised insulitis and beta-cell
destruction. In some diabetic patients, the plasma concen-
tration and activity of α1-PI was found to be decreased
Fig. 7 α1-PI is released by islet cells. a After a 2-h incubation in
control medium, a minority of islet cells secreted α1-PI, and are
seen surrounded by circular haemolytic plaques, containing dark
ghosts of complement-lysed erythrocytes (left). Immunostaining for
insulin (right) revealed that beta cells were not surrounded by
haemolytic plaques, which were always centred on non-beta cells.
Inserts show one cell surrounded by a haemolytic plaque, which
stained positively for α1-PI. Scale bar: 30 μm. b Islet cells were
cultured in serum-free medium, in the absence (−Dex) or presence
(+Dex) of 1 μmol/l dexamethasone. Standard medium (control) was
supplemented with 0.5 mmol/l IBMX, 20 ng/ml IL-1β or 20 ng/ml
OSM. Aliquots of supernatant were taken after 4 days in culture and
α1-PI content measured by ELISA. Results of control, IL-1β, OSM
(four experiments) and IBMX (two experiments) are means±SEM.
*p<0.001 when compared to control in the presence of dexameth-
asone. c Islet cells were cultured as described (b). Aliquots of
medium were taken after 4 days of culture and insulin release
measured by ELISA. Data show that only IBMX affected insulin
release, both in the absence (−Dex) and presence of dexamethasone
(+Dex). Results are expressed as means±SEM of six experiments for
control, IL-1β and OSM, and four experiments for IBMX. *p<0.005
and **p<0.05 when compared with the corresponding condition
without dexamethasone. d Islet cells were cultured as described (b).
After 4 days, the cells were rinsed and incubated in control medium
for 1 h. Aliquots of culture supernatant were taken and α1-PI
content measured by ELISA. In the absence of dexamethasone
(−Dex), results are means±SEM of two experiments. ND, non-
determined. In the presence of dexamethasone (+Dex), results are
means±SEM of three experiments for all conditions, except for
IBMX where n=1. *p<0.05 compared with the control in the
presence of dexamethasone
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compared with controls [53–55], but the pathogenesis of
this finding was not investigated.
In addition to a possible role in regulating cell injury
induced by inflammatory cytokines, we propose that α1-
PI, produced by the pancreatic alpha and delta cells, may
also act as an antiprotease against enzymes released by the
surrounding exocrine tissue. In this perspective, alpha and
delta cells could protect the more centrally located islet
cells, mostly beta cells. This function could be particularly
important during the development of acute pancreatitis
when leakage of aggressive enzymes from surrounding
inflamed acinar cells is expected.
Finally, our results show that islet cells are able to release
α1-PI. We measured a higher concentration of α1-PI in the
culture supernatant after cytokine treatment. This increase
is accounted for by a higher synthesis of α1-PI after
cytokine treatment, than by a major increment in the release
of the inhibitor. When islet cells treated with cytokines
were further incubated in control medium, they continued
to release more α1-PI than untreated cells. These obser-
vations suggest that α1-PI in islet cells is secreted in a
constitutive manner.
In summary, our results clearly show that human islet
alpha and delta cells express and secrete α1-PI, and that
these events are modulated by cytokines. Taken together
our data suggest that local production of α1-PI in islets
may be triggered by inflammatory processes that occur at
the onset of diabetes, the development of acute pancreatitis
and conditions perturbing the native islet environment,
such as transplantation. Further studies should determine
whether and how α1-PI is involved in these pathological
conditions.
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